1. Home
  2. DEC vs GERN Comparison

DEC vs GERN Comparison

Compare DEC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diversified Energy Company plc

DEC

Diversified Energy Company plc

HOLD

Current Price

$15.77

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEC
GERN
Founded
2001
1990
Country
United States
United States
Employees
N/A
229
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
DEC
GERN
Price
$15.77
$1.70
Analyst Decision
Strong Buy
Hold
Analyst Count
7
3
Target Price
$22.00
$2.17
AVG Volume (30 Days)
1.2M
19.2M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
7.46%
N/A
EPS Growth
311.06
N/A
EPS
4.58
N/A
Revenue
$1,829,142,000.00
N/A
Revenue This Year
$23.30
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
$3.39
N/A
Revenue Growth
141.54
N/A
52 Week Low
$11.21
$1.04
52 Week High
$18.90
$2.01

Technical Indicators

Market Signals
Indicator
DEC
GERN
Relative Strength Index (RSI) 47.55 54.06
Support Level $14.04 $1.24
Resistance Level $16.09 $1.72
Average True Range (ATR) 0.68 0.10
MACD -0.28 0.01
Stochastic Oscillator 7.52 68.49

Price Performance

Historical Comparison
DEC
GERN

About DEC Diversified Energy Company plc

Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: